<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489033</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-PHL-P1-001</org_study_id>
    <secondary_id>2009-015000-26</secondary_id>
    <nct_id>NCT01489033</nct_id>
  </id_info>
  <brief_title>Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense</brief_title>
  <official_title>Multicentre Phase I Randomized Double Blind Placebo Controlled Study of Subcutaneous Immunotherapy in Subjects With Allergic Rhinoconjunctivitis ± Asthma Sensitised to Phleum Pratense.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roxall Medicina España S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roxall Medicina España S.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on EMA (European Medicines Agency) new guidelines on the clinical development of&#xD;
      products for immunotherapy for the treatment of allergic disease the aim of this study was to&#xD;
      assess safety and tolerability of three different subcutaneous immunotherapy dose escalations&#xD;
      in patients allergic to the pollen of Phleum pratense.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and seriousness of both local and systemic adverse reactions</measure>
    <time_frame>From informed consent signature (V0) until the end of patient participation in the study (depending on the treatment assigned between 4 and 8 weeks )</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin levels (IgE specific, IgG total and IgG4) and prick test dose response</measure>
    <time_frame>Before (V0) and after treatment (depending on the treatment assigned between 4 and 8 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Group A active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 administrations and 5 weeks duration&#xD;
Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals&#xD;
Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 administrations and 5 weeks duration&#xD;
Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals&#xD;
Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 administrations and 7 weeks duration&#xD;
Vial 1: 0.2 ml at 1 week intervals&#xD;
Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals&#xD;
Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 administrations and 7 weeks duration&#xD;
Vial 1: 0.2 ml at 1 week intervals&#xD;
Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals&#xD;
Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.&#xD;
Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval&#xD;
Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval&#xD;
Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval&#xD;
Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.&#xD;
Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval&#xD;
Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval&#xD;
Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval&#xD;
Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Subcutaneous immunotherapy with Phleum pratense pollen extract</intervention_name>
    <description>Increasing doses up to a maximum dose of 500 TSU</description>
    <arm_group_label>Group A active</arm_group_label>
    <arm_group_label>Group A placebo</arm_group_label>
    <arm_group_label>Group B active</arm_group_label>
    <arm_group_label>Group B placebo</arm_group_label>
    <arm_group_label>Group C active</arm_group_label>
    <arm_group_label>Group C placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must sign the informed consent form.&#xD;
&#xD;
          2. Patients must be between 18 and 60 years of age.&#xD;
&#xD;
          3. Patients who obtained a prick test result greater or equal to 3 mm diameter and a&#xD;
             specific IgE greater or equal to class 2 (CAP/PHADIA) to Phleum pratense.&#xD;
&#xD;
          4. Patients with seasonal allergic rhinoconjunctivitis against Phleum pratense during a&#xD;
             minimum of 2 years prior to study participation. Although allergic rhinoconjunctivitis&#xD;
             is the pathology under study, the inclusion of patients with mild or moderate&#xD;
             concomitant asthma is allowed.&#xD;
&#xD;
          5. Patients will preferably be monosensitized to Phleum pratense. Polysensitized patients&#xD;
             to other seasonal allergens will be accepted if sensitizations are caused by Pollens&#xD;
             whose seasons do not overlap with Phleum pratense.&#xD;
&#xD;
             Polysensitized patients to perennial allergens will also be accepted if not clinically&#xD;
             relevant during the study period.&#xD;
&#xD;
          6. Women of childbearing potential must have a negative urine pregnancy test at Screening&#xD;
             visit/Visit 0&#xD;
&#xD;
          7. Women of childbearing potential must agree to use an appropriate contraception method&#xD;
             during the study if they are sexually active.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Stable and continued use of medication for allergic pathology during 2 weeks prior to&#xD;
             inclusion.&#xD;
&#xD;
          2. Patients sensitised to other overlapping seasonal allergens and with specific IgE&#xD;
             levels greater or equal to class 2 CAP/PHADIA.&#xD;
&#xD;
          3. Patients who received immunotherapy in the previous 5 years for Phleum pratense or for&#xD;
             any allergen with cross reactivity or patients that are currently receiving&#xD;
             immunotherapy for any allergen.&#xD;
&#xD;
          4. Patients with severe asthma or FEV1 lower than 60% or asthma requiring inhaled or&#xD;
             systemic corticoid treatment at the time of study entry or within 8 weeks prior to&#xD;
             treatment commencement.&#xD;
&#xD;
          5. Patients with: immunological, cardiac, renal or hepatic illnesses or any other medical&#xD;
             condition that the investigator deems relevant so as to interfere with the study.&#xD;
&#xD;
          6. Patients with a previous history of anaphylaxis&#xD;
&#xD;
          7. Patients with unstable angina&#xD;
&#xD;
          8. Patients with uncontrolled hypertension&#xD;
&#xD;
          9. Patients with clinically significant arrythmias&#xD;
&#xD;
         10. Patients with neoplasia&#xD;
&#xD;
         11. Patients with clinically relevant malformations of the upper respiratory tract.&#xD;
&#xD;
         12. Other chronic or immunological disease that could interfere with the assessment of the&#xD;
             investigation product or that could generate any additional risk for the patient&#xD;
&#xD;
         13. Patients who have participated in another clinical trial within 3 month prior to&#xD;
             enrolment.&#xD;
&#xD;
         14. Patients under treatment with tricyclic antidepressives, psychotropics or&#xD;
             beta-blockers&#xD;
&#xD;
         15. Female patients who are pregnant or breast-feeding or women of childbearing potential&#xD;
             that do not agree to use an appropriate contraception method during the study if they&#xD;
             are sexually active, if they have not been surgical sterilised or present any other&#xD;
             incapacity to bear&#xD;
&#xD;
         16. Patient who does not attend the visits&#xD;
&#xD;
         17. Patient's lack of collaboration or refusal to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilio Álvarez-Cuesta, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>December 7, 2011</study_first_submitted>
  <study_first_submitted_qc>December 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2011</study_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic rhinitis</keyword>
  <keyword>Phleum pratense</keyword>
  <keyword>Timothy grass pollen allergy</keyword>
  <keyword>subcutaneous immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

